Your browser doesn't support javascript.
loading
Analysis of HLA-G 14 bp Insertion/Deletion Polymorphism and HLA-G, ILT2 and ILT4 Expression in Head and Neck Squamous Cell Carcinoma Patients.
Durmanova, Vladimira; Tedla, Miroslav; Rada, Dusan; Bandzuchova, Helena; Kuba, Daniel; Suchankova, Magda; Ocenasova, Agata; Bucova, Maria.
Afiliação
  • Durmanova V; Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
  • Tedla M; Department of Ears, Nose and Throat and Head and Neck Surgery, Faculty of Medicine, University Hospital Bratislava, Comenius University in Bratislava, 851 07 Bratislava, Slovakia.
  • Rada D; Department of Ears, Nose and Throat and Head and Neck Surgery, Faculty of Medicine, University Hospital Bratislava, Comenius University in Bratislava, 851 07 Bratislava, Slovakia.
  • Bandzuchova H; National Transplant Organisation, 831 01 Bratislava, Slovakia.
  • Kuba D; National Transplant Organisation, 831 01 Bratislava, Slovakia.
  • Suchankova M; Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
  • Ocenasova A; Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
  • Bucova M; Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Diseases ; 12(2)2024 Feb 08.
Article em En | MEDLINE | ID: mdl-38391781
ABSTRACT
HLA-G is the checkpoint molecule involved in the suppression of the immune response. Increased expression of HLA-G and its ILTs receptors have been correlated with tumor progression in various cancer types. In head and neck squamous cell carcinoma (HNSCC) tumors, the effect of HLA-G, ILT2 and ILT4 expression on cancer development has to be explained. The 34 HNSCC patients and 98 controls were genotyped for the HLA-G 14 bp ins/del polymorphism. In HNSCC lesions, HLA-G, ILT2 and ILT4 mRNA expression was analysed using real-time PCR. The association between HLA-G, ILT2 and ILT4 mRNA expression and clinical variables (age at onset, TNM staging system and p16 positivity) was also evaluated. No genetic association between the HLA-G 14 bp ins/del and HNSCC risk was detected (p > 0.05). However, in the non-metastatic HNSCC group, a significantly higher HLA-G mRNA expression was noted in tumors in the T4 stage compared to those in the T1 and T2 stages (p = 0.0289). ILT2 mRNA expression was significantly increased in non-metastatic vs. metastatic tumors (p = 0.0269). Furthermore, a significantly higher ILT4 mRNA expression was noted in tumors in the T1+T2 stage compared to those in the T3 stage (p = 0.0495). Our results suggest that the HLA-G molecule creates an immunological microenvironment involved in HNSCC development.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article